Drugs / VSVG-ZEBOV
VSVG-ZEBOV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02344407 | Jan 2015 → Jun 2016 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSVG-ZEBOV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02344407 ↗ |
| Known as | ERVEBO | “BACKGROUND: ERVEBO®, a live recombinant vesicular stomatitis virus (VSV) vaccine containing the Zaire ebolavirus glycoprotein (GP) in place of the VSV GP (rVSVΔG-ZEBOV-GP), was...” PMID 36208978 ↗ Oct 2022 |
| Known as | rVSVΔG-ZEBOV-GP | “BACKGROUND: ERVEBO®, a live recombinant vesicular stomatitis virus (VSV) vaccine containing the Zaire ebolavirus glycoprotein (GP) in place of the VSV GP (rVSVΔG-ZEBOV-GP), was...” PMID 36208978 ↗ Oct 2022 |
| Known as | V920 | “The vaccine referred to as V920 is a recombinant vesicular stomatitis virus (rVSV) in which the VSV-G envelope glycoprotein (GP) is completely replaced by the Zaire ebolavirus...” PMID 28647166 ↗ Jun 2017 |
| Known as | VSVdeltaG-ZEBOV | “The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope...” NCT02344407 ↗ |
| Modality | Vaccine | “The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope...” NCT02344407 ↗ |